A Phase 3 interventional study of LUM and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 27 sites in 2 countries. Open to participants aged 12 Months to 23 Months. Per ClinicalTrials.gov, last updated 2023-01-06.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 12th largest by enrollment, is one of 2 that started in 2018, is one of 10 in phase 3, and was the 18th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2018.
This study's enrollment of 61 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 71st largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 62 in phase 3, and was the 79th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and pharmacokinetics (PK) of lumacaftor (LUM) and ivacaftor (IVA) in participants 1 to less than 2 years of age with cystic fibrosis (CF), homozygous for F508del (F/F).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants weighing 7 to less than (\<)10 kilograms (kg) at screening received LUM 75 milligrams (mg)/IVA 94 mg fixed-dose combination (FDC) every 12 hours (q12h) and those weighing 10 to \<14 kg at screening received LUM 100 mg/IVA 125 mg q12h for 15 days. Participants weighing greater than or equal to (\>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 15 days.
Drug: LUM · Drug: IVA
Participants weighing 7 to \<9 kg at screening received LUM 75 mg/IVA 94 mg FDC q12h and those weighing 9 to \<14 kg received LUM 100 mg/IVA 125 mg q12h for 24 weeks. Participants weighing \>=14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 24 weeks. Doses were adjusted upwards for changes in weight.
Drug: LUM · Drug: IVA
Part A: Observed Plasma Concentrations From 3-4 Hours (C3-4hr) of LUM and IVA
Time frame: Day 1 and Day 15
Part A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA
Time frame: Pre-dose at Day 8 and Day 15
Part B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Week 26
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Day 25
Part A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)
Time frame: Pre-dose at Day 8 and Day 15
Part B: Absolute Change in Sweat Chloride
Time frame: From Baseline at Week 24
Part B: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)
Time frame: Pre-dose at Day 15, Week 4, Week 12 and Week 24
| Milestone | Part A: LUM/IVA | Part B: LUM/IVA |
|---|---|---|
| Started | 14 | 46 |
| Completed | 13 | 43 |
| Not completed | 1 | 3 |
| Withdrew: Withdrawal of consent (not due to adverse event) | 0 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Other | 0 | 1 |
| nanograms per milliliter (ng/mL) | Part A: LUM 75 mg/IVA 94 mg | Part A: LUM 100 mg/IVA 125 mg |
|---|---|---|
| Day 1: LUM | 14600 ± 5560 | 12600 ± 7190 |
| Day 15: LUM | 16600 ± 9590 | 13900 ± 5800 |
| Day 1: IVA | 1620 ± 648 | 1320 ± 804 |
| Day 15: IVA | 718 ± 352 | 496 ± 268 |
| ng/mL | Part A: LUM 75 mg/IVA 94 mg | Part A: LUM 100 mg/IVA 125 mg |
|---|---|---|
| Day 8: LUM | 12000 ± 8880 | 12800 ± 3900 |
| Day 15: LUM | 8380 ± 7790 | 10500 ± 3070 |
| Day 8: IVA | 169 ± 75.5 | 185 ± 101 |
| Day 15: IVA | 78.9 ± 19.1 | 120 ± 60.5 |
| participants | Part B: LUM/IVA |
|---|---|
| Participants with TEAEs | 44 |
| Participants with SAEs | 5 |
| participants | Part A: LUM/IVA |
|---|---|
| Participants with TEAEs | 12 |
| Participants with SAEs | 0 |
| ng/mL | Part A: LUM 75 mg/IVA 94 mg | Part A: LUM 100 mg/IVA 125 mg |
|---|---|---|
| Day 8: M28-LUM | 1410 ± 791 | 1470 ± 365 |
| Day 15: M28-LUM | 1460 ± 1060 | 1370 ± 468 |
| Day 8: M1-IVA | 606 ± 298 | 842 ± 527 |
| Day 15: M1-IVA | 284 ± 70.2 | 604 ± 394 |
| Day 8: M6-IVA | 2380 ± 843 | 3290 ± 1830 |
| Day 15: M6-IVA | 1460 ± 763 | 2800 ± 2300 |
| Millimole per liter (mmol/L) | Part B: LUM/IVA |
|---|---|
| Part B: Absolute Change in Sweat Chloride | -29.1 ± 13.5 |
| ng/mL | Part B: LUM 75 mg/IVA 94 mg | Part B: LUM 100 mg/IVA 125 mg | Part B: LUM 150 mg/IVA 188 mg |
|---|---|---|---|
| Day 15: LUM | 13500 | 9030 ± 4390 | 887 |
| Week 4: LUM | 21900 | 9370 ± 5030 | 1000 |
| Week 12: LUM | 12100 | 9160 ± 4400 | 566 |
| Week 24: LUM | 11200 | 8930 ± 5310 | 288 |
| Day 15: M28-LUM | 1460 | 1260 ± 528 | 786 |
| Week 4: M28-LUM | 1570 | 1340 ± 579 | 602 |
| Week 12: M28-LUM | 1740 | 1440 ± 599 | 501 |
| Week 24: M28-LUM | 1870 | 1470 ± 548 | 569 |
| Day 15: IVA | 213 | 112 ± 68.3 | 3.68 |
| Week 4: IVA | 267 | 112 ± 82.9 | 11.4 |
| Week 12: IVA | 286 | 91.7 ± 44.7 | 2.18 |
| Week 24: IVA | 37.1 | 144 ± 296 | 2.86 |
| Day 15: M1-IVA | 1420 | 437 ± 291 | 18.1 |
| Week 4: M1-IVA | 1930 | 466 ± 359 | 58.0 |
| Week 12: M1-IVA | 759 | 418 ± 236 | 18.3 |
| Week 24: M1-IVA | 256 | 499 ± 613 | 18.5 |
| Day 15: M6-IVA | 4740 | 1930 ± 1460 | 43.9 |
| Week 4: M6-IVA | 9090 | 1970 ± 1490 | 131 |
| Week 12: M6-IVA | 3520 | 1950 ± 1430 | 46.5 |
| Week 24: M6-IVA | 1320 | 1740 ± 1130 | 63.3 |
Collected over From Day 1 Through Safety Follow-up Period (up to Day 25 for Part A and up to Week 26 for Part B). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: LUM/IVA | 0/14 (0%) | 0/14 (0%) | 12/14 (85.7%) |
| Part B: LUM/IVA | 0/46 (0%) | 5/46 (10.9%) | 42/46 (91.3%) |
| Event | Part A: LUM/IVA | Part B: LUM/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/14 | 3/46 |
| Post procedural feverInjury, poisoning and procedural complications | 0/14 | 1/46 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/14 | 1/46 |
| Event | Part A: LUM/IVA | Part B: LUM/IVA |
|---|---|---|
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 5/14 | 5/46 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/14 | 16/46 |
| PyrexiaGeneral disorders | 1/14 | 10/46 |
| RashSkin and subcutaneous tissue disorders | 3/14 | 4/46 |
| VomitingGastrointestinal disorders | 0/14 | 8/46 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/14 | 8/46 |
| InfluenzaInfections and infestations | 2/14 | 0/46 |
| Upper respiratory tract infectionInfections and infestations | 1/14 | 6/46 |
| Pseudomonas test positiveInvestigations | 0/14 | 5/46 |
| ConstipationGastrointestinal disorders | 1/14 | 5/46 |
All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis. The baseline analysis was collected for the overall treatment arm, irrespective of a weight-based dose regimen. Therefore, the analysis is reported in a single arm for each study part (Part A: LUM/IVA and Part B: LUM/IVA).
| Age, Categorical(Participants) | Part A: LUM/IVA | Part B: LUM/IVA | Total |
|---|---|---|---|
| <=18 years | 14 | 46 | 60 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A: LUM/IVA | Part B: LUM/IVA | Total |
|---|---|---|---|
| Female | 7 | 24 | 31 |
| Male | 7 | 22 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Part A: LUM/IVA | Part B: LUM/IVA | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 13 | 37 | 50 |
| Unknown or Not Reported | 0 | 7 | 7 |
| Race/Ethnicity, Customized(Participants) | Part A: LUM/IVA | Part B: LUM/IVA | Total |
|---|---|---|---|
| White | 14 | 34 | 48 |
| Black or African American | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Not collected per local regulations | 0 | 7 | 7 |
| Other | 0 | 3 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Sep 2018 to primary completion in Oct 2021, 37 months.
Results were first posted in Jan 2023, 1 year 2 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 37 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lumacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →